Nghiên cứu kết quả điều trị và một số yếu tố tiên lượng ung thư biểu mô nội mạc tử cung giai đoạn I,II

Abstract

1. Results on 186 patients of endometrial cancer stage I and II underwent surgery, with or without adjuvant treatment based on the standard guideline have shown the mortality rate was 15.1%, the recurrence rate was 8.1%, metastasis rate is 16.7%. DFS for 5 years was 74.6%. 5 years OS was 79.9%.

2. The study has demonstrated a clear association of many factors with prognosis. Non-endometrioid endometrial carcinoma has a 4.1fold higher risk of death. Highgrade has 4.9 times higher mortality risk than intermediate and lơ grade. The group of ER(-) PR (-) has 24 times higher mortality risk than ER (+) PR (+ ), lymph node metastases are 11.9 times more likely to die without lymph node metastases. At the same time, multivariate analysis showed that histopathology, PR receptor, lymph node metastasis are independent prognostic factors in endometrial cancer. Identifying prognostic factors during treatment is extremely important to help improve the effectiveness of treatment.